Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized phase II study of cisplatin/carboplatin and docetaxel in combination with cetuximab for stage IV NSCLC
2009-016806-18Phase 2Terminated
- Sponsor
- Klinik Löwenstein
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cetuximab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Klinik Löwenstein. Primary endpoint: Progression-free survival rate at 24 weeks. Started Sep 2010; status: terminated.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-016806-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016806-18.